Merck Animal and Health

What Merck Animal and Health does

Merck Animal Health operates as the animal-health division of Merck & Co., Inc. (NYSE: MRK), a publicly traded pharmaceutical corporation headquartered at 126 E. Lincoln Ave., Rahway, New Jersey. The division markets BRAVECTO, a prescription-only parasiticide franchise for companion animals (dogs and cats), distributed exclusively through licensed veterinarians and authorized online pet retailers in the United States. The franchise addresses flea and tick prevention and, in feline formulations, additional endoparasites, and serves US pet owners via a veterinarian-gated prescription model with rebate incentives ($20–$100) that reward veterinary-clinic-channel purchases.

The BRAVECTO product line is built on fluralaner, a proprietary isoxazoline-class active ingredient originally FDA-approved in 2014 (NADA 141-426) for canine oral use. The portfolio includes BRAVECTO Chews (12-week oral, dogs), BRAVECTO Topical Solution (12-week topical, dogs and cats), BRAVECTO 1-MONTH Chews for Puppies (2024 launch), BRAVECTO PLUS for Cats (2019 launch, combining fluralaner with moxidectin for fleas, ticks, heartworms, roundworms, hookworms), and BRAVECTO Quantum (2025 launch), the first injectable flea and tick treatment providing 12-month protection in a single veterinarian-administered dose. Differentiated technical elements include extended-release injectable suspension technology, a Twist'n'Use topical applicator, and labeled coverage of up to six tick species in dogs (including the Asian longhorned tick), with clinical claims of 100% tick kill within 12 hours and 93%+ voluntary acceptance of the chew formulation in US field studies.

The business model is prescription pharmaceutical sales through a veterinary-recommendation go-to-market motion. Veterinarians act as gatekeepers, prescribing and dispensing products (with BRAVECTO Quantum administered in-clinic), while authorized online pet pharmacies fill prescriptions on a valid-vet-prescription basis. Revenue is generated through per-dose prescription transactions rather than subscription or enterprise contracts, with rebate programs (Merck Visa Prepaid Card) layered in to drive multi-dose purchases and channel loyalty. The brand supports its veterinary channel with a vet locator tool, social media presence (Facebook, Instagram, YouTube), educational content on flea/tick-borne disease, video testimonials from practicing veterinarians, and the BRAVECTO Cares CSR partnership with NEADS. Geographic scope is explicitly limited to the United States (all 50 states and the District of Columbia) per rebate terms.

Name

Merck Animal and Health

Legal name

Merck & Co., Inc.

Website

https://bravecto.com

Company type

Public

Operating status

Operating

Short description

Merck Animal Health (division of Merck & Co., NYSE: MRK) markets BRAVECTO, a prescription parasiticide franchise for dogs and cats built on fluralaner, sold exclusively through US veterinarians and authorized online retailers across chew, topical, and 12-month injectable formulations.

Ownership category

akta.pro rank

Headquarters

HQ city

Rahway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Revenue model

1. Veterinary Prescription Pharmaceutical Sales: BRAVECTO products are sold as prescription-only veterinary pharmaceuticals distributed exclusively through licensed veterinarians and authorized online pet retailers. Pet owners obtain prescriptions through veterinary consultations and purchase products at veterinary clinics or through authorized online pharmacies with valid prescriptions.
2. Rebate Programs: The company operates rebate programs for pet owners who purchase BRAVECTO and SENTINEL products from veterinary clinics. Rebates range from $20-$100 depending on product combination, with maximum lifetime caps per household. Rebates are fulfilled via Merck Visa Prepaid Card.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

Merck Animal Health, through its BRAVECTO brand, manufactures and sells prescription-only veterinary pharmaceutical products that protect dogs and cats against fleas, ticks, and (for cats) heartworms and intestinal parasites. The BRAVECTO portfolio includes extended-release injectables, oral chews, and topical solutions containing the proprietary active ingredient fluralaner, with protection durations ranging from 1 month to 12 months per dose. Products are dispensed through licensed veterinarians and authorized online pet retailers.

Differentiator

Problem solved

Functional benefit

Products and services

• BRAVECTO Quantum for Dogs First and only injectable flea and tick treatment for dogs providing 12 months of protection with a single veterinarian-administered injection. Contains the proprietary active ingredient fluralaner in an extended-release injectable suspension; kills adult fleas and treats/controls black-legged, American dog, brown dog, Asian longhorned, and Gulf Coast ticks for 12 months, and lone star ticks for 8 months. For dogs; dispensed by prescription only through veterinary clinics.
• BRAVECTO Chews for Dogs Oral chewable flea and tick treatment for dogs providing 12 weeks of protection with single-dose administration. Contains fluralaner; kills adult fleas and multiple tick species (black-legged, American dog, brown dog, Asian longhorned). Over 93% of dogs ate the chew voluntarily in US field studies. Available by prescription only through licensed veterinarians.
• BRAVECTO Topical Solution for Dogs

Quantifiable outcome

• Over 93% of dogs ate the BRAVECTO Chew voluntarily in US field studies
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• NEADS (National Education for Assistance Dog Services)flagshipStrategic or Co-development PartnerBRAVECTO Cares program partners with NEADS, an organization that trains and provides World Class Service Dogs for people with disabilities. Merck Animal Health provides flea and tick protection products (BRAVECTO), vaccines, and financial support to NEADS to help maintain the health of service dogs in training. This partnership helps NEADS maintain their training programs while demonstrating BRAVECTO's commitment to animal welfare and community service.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Phibro Animal Health: Animal health company with nutritional and pharmaceutical products for livestock and companion animals. Touches BRAVECTO's broader animal health category but with a livestock-heavy mix.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company focused on companion animal endocrinology, dermatology, and parasiticides. Competes indirectly via shared vet channel and complementary therapeutic areas.
• Virbac: Global animal health company with a parasiticide portfolio including effitix and other topical flea/tick products. Competes in the same veterinary channel with broader specialty and pharma offerings beyond parasiticides.
• Vetoquinol: European-headquartered animal health company with companion-animal parasiticide and pharmaceutical lines. Operates in similar vet-prescription channels and overlaps with BRAVECTO in flea/tick and dermatology categories.
• Ceva Santé Animale: Major veterinary pharmaceutical group marketing combination parasiticide products (e.g., Vectra, Catego) for companion animals in the US and globally. Overlaps with BRAVECTO on flea/tick prevention across cats and dogs.

Others

• IDEXX Laboratories: Companion animal diagnostics and practice management vendor. Not a parasiticide competitor, but a major beneficiary of veterinary clinic economics and a complementary player in the same vet-prescribed care ecosystem BRAVECTO depends on.

Direct peers

• Seresto (Elanco/Bayer): Seresto is an over-the-counter flea and tick collar (imidacloprid + flumethrin) competing with BRAVECTO on long-duration flea/tick protection. Different delivery format but same end-customer need and competes for the same household budget allocation.
• Zoetis (Simparica): Zoetis markets Simparica/Simparica Trio (sarolaner + moxidectin), a direct competitor across flea, tick, and heartworm prevention in dogs and cats. Same prescription-vet channel and isoxazoline mechanism; competes aggressively on duration and combination coverage.
• Elanco Animal Health (Credelio): Elanco markets Credelio (lotilaner), another isoxazoline parasiticide competing directly with BRAVECTO in the vet-prescribed flea and tick space. Comparable target customer, channel, and product positioning.
• Boehringer Ingelheim Animal Health (NexGard): Maker of NexGard (afoxolaner), a direct competitor to BRAVECTO Chews for oral flea and tick protection in dogs. Same isoxazoline class, same veterinary-prescription channel, same duration profile — the closest head-to-head competitor in US companion animal parasiticides.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@bravecto_us
• Facebookfacebook.com/bravectoUS
• Instagraminstagram.com/bravecto.us

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Animal and Health